Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer

This study is testing a combination of three treatments — adebrelimab (immunotherapy), apatinib (a targeted drug that cuts off blood supply to tumors), and SOX chemotherapy — as a "conversion therapy" for people with advanced stomach or gastroesophageal junction cancer that cannot currently be surgically removed. The goal is to shrink the cancer enough to make surgery possible. **You may be eligible if:** - You are aged 18 to 75 with good general health - You have locally advanced stomach or gastroesophageal junction cancer (mainly adenocarcinoma) that is unresectable (cannot be removed by surgery right now) - You have never received any cancer treatment before (no chemotherapy, radiation, or immunotherapy) - Your blood counts and organ function are within acceptable ranges - You are willing to use contraception during and for at least 12 weeks after treatment **You may NOT be eligible if:** - Your cancer is HER2-positive (a specific protein marker) - You have difficulty swallowing or persistent nausea that would prevent taking oral medications - You have active autoimmune disease or immune deficiency - You have severe lung disease or uncontrolled high blood pressure - You have had a prior organ or stem cell transplant - You have had a serious infection within the past 4 weeks Talk to your doctor to see if this trial is right for you.